CureVac Shareholders Face Critical Deadline in BioNTech Takeover Bid

Time is running out for investors in CureVac as they approach a decisive moment in the company’s proposed acquisition by fellow German biotech firm BioNTech. Shareholders have until December 3 to participate in the exchange offer that would see their CureVac holdings converted into BioNTech stock.

The share exchange proposal, which commenced on October 22, presents CureVac investors with approximately $5.46 in BioNTech shares for each CureVac share they own. However, the precise conversion ratio operates under a sophisticated mechanism tied to BioNTech’s stock performance. The arrangement allows for between 0.04318 and 0.06476 BioNTech American Depositary Shares (ADS) per CureVac share, creating strategic considerations for investors attempting to optimize the timing of their exchange Read more...